The two most powerful weight-loss medications in modern medicine are semaglutide and tirzepatide. Both belong to the GLP-1 family, both are delivered as a once-weekly injection, and both consistently outperform every previous generation of anti-obesity drug.
But they are not the same molecule, and the results are not the same either. Tirzepatide activates a second gut hormone receptor (GIP) alongside GLP-1, which changes how it feels and how it performs in real-world clinics.
Here is what patients actually need to know before choosing between them.
The Mechanism Difference
Semaglutide is a single-agonist: it targets the GLP-1 receptor. Tirzepatide is a dual-agonist: it targets GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). Both hormones are released after eating and both improve insulin sensitivity, but GIP also plays a role in energy expenditure and fat metabolism.
Adding GIP activation is why tirzepatide tends to produce greater weight loss in head-to-head data — and why some patients tolerate it better despite the higher potency.
Head-to-Head Efficacy
In the SURMOUNT-1 trial, adults with obesity taking the highest tirzepatide dose (15 mg weekly) lost an average of 20.9% of their body weight over 72 weeks. Semaglutide (2.4 mg weekly) produced an average of 14.9% loss in the STEP-1 trial over 68 weeks.
In a direct comparison (SURMOUNT-5, 2024), tirzepatide outperformed semaglutide by roughly 47% more total weight lost in adults with obesity without diabetes. For patients with significant weight to lose, that gap is clinically meaningful.
Side-Effect Profiles
Both medications share the same GI side-effect profile: nausea, constipation, and reflux, mostly during titration. Tirzepatide is often described by patients as feeling smoother — likely because the added GIP activation blunts some of the nausea signaling that pure GLP-1s produce.
That said, individual response varies. A patient who is miserable on semaglutide may thrive on tirzepatide, and vice versa. This is one reason Summit protocols include a switch pathway if the first medication is not tolerated.
Cost and Access
Both branded versions (Wegovy for semaglutide, Zepbound for tirzepatide) run over $1,000 per month at retail without insurance. Compounded versions, prescribed by a licensed clinician through a 503A pharmacy, dramatically reduce that cost.
Summit uses compounded formulations through vetted US pharmacies, delivered directly to your door. Pricing is transparent and cash-based — no insurance games, no surprise bills.
Who Should Choose Which?
Semaglutide tends to be the better first choice for patients with 20 to 40 pounds to lose, patients who are highly sensitive to medications, and patients with a stronger metabolic profile.
Tirzepatide tends to be the better choice for patients with 40+ pounds to lose, patients with insulin resistance or type 2 diabetes, and patients who have plateaued on semaglutide.
But the clinical picture matters more than any general rule. Your history, labs, medications, and goals should drive the decision — not a friend's recommendation or a social media trend.
Both Only Work Inside a Program
Neither drug is a monotherapy. Both require adequate protein, resistance training, and a taper plan to protect lean mass and prevent regain. Summit builds all three around the medication — because the medication is a tool, not a solution.
Not Sure Which One Is Right?
Take the assessment. A Summit clinician will review your history and recommend the right protocol.
Start Your Consultation